Retigeric acid B enhances the efficacy of azoles combating the virulence and biofilm formation of Candida albicans

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 10, 2012, Pages 1794-1801

  Chang, Wenqiang ^a   Li, Ying ^a   Zhang, Li ^a   Cheng, Aixia ^a   Liu, Yongqing ^a   Lou, Hongxiang ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Biofilm; Candida albicans; Hyphae; Synergistic; Virulence

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; RETIGERIC ACID B; TRITERPENOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CANDIDIASIS; CDR1 GENE; CELL INVASION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FUNGAL VIRULENCE; FUNGUS HYPHAE; GENE; GENETIC TRANSCRIPTION; HOST PATHOGEN INTERACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MDR1 GENE; MONOTHERAPY; MOUSE; NONHUMAN;

ANIMALS; ANTIFUNGAL AGENTS; BIOFILMS; CACO-2 CELLS; CANDIDA ALBICANS; CANDIDIASIS; DRUG SYNERGISM; FLUCONAZOLE; FUNGAL PROTEINS; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, INBRED BALB C; P-GLYCOPROTEIN; TRITERPENES; VIRULENCE;

EID: 84867269494     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00511     Document Type: Article

References (31)

1. Noverr MC, Huffnagle GB. Regulation of Candida albicans morphogenesis by fatty acid metabolites. Infect. Immun., 72, 6206-6210 (2004).
2. Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ. The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J. Bacteriol., 178, 5353-5360 (1996).
3. Kumamoto CA, Vinces MD. Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell. Microbiol., 7, 1546-1554 (2005).
4. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol., 183, 5385-5394 (2001).
5. Douglas LJ. Candida biofilms and their role in infection. Trends Microbiol., 11, 30-36 (2003).
6. LaFleur MD, Kumamoto CA, Lewis K. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob. Agents Chemother., 50, 3839-3846 (2006).
7. Hawser SP, Douglas LJ. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother., 39, 2128-2131 (1995).
8. Ramage G, VandeWalle K, López-Ribot JL, Wickes BL. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol. Lett., 214, 95-100 (2002).
9. Lichen Biology (Elix JA, Nash TH. III eds.) Charpter 9, Cambridge University Press, New York, pp. 176-178 (1996).
10. Huneck S, Yoshimura I. Identification of lichen substances, Springer Verlag, Berlin (1996).
11. Sun LM, Cheng AX, Wu XZ, Zhang HJ, Lou HX. Synergistic mechanisms of retigeric acid B and azoles against Candida albicans. J. Appl. Microbiol., 108, 341-348 (2010).
12. Larsen B, Anderson S, Brockman A, Essmann M, Schmidt M. Key physiological differences in Candida albicans CDR1 induction by steroid hormones and antifungal drugs. Yeast, 23, 795-802 (2006).
13. Xi GM, Sun B, Jiang HH, Kong F, Yuan HQ, Lou HX. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. Bioorg. Med. Chem., 18, 6725-6733 (2010).
14. Dalle F, Wächtler B, L'Ollivier C, Holland G, Bannert N, Wilson D, Labruère C, Bonnin A, Hube B. Cellular interactions of Candida albicans with human oral epithelial cells and enterocytes. Cell. Microbiol., 12, 248-271 (2010).
15. Norice CT, Smith Jr FJ, Solis N, Filler SG, Mitchell AP. Requirement for Candida albicans Sun41 in biofilm formation and virulence. Eukaryot. Cell, 6, 2046-2055 (2007).
16. Braga PC, Culici M, Alfieri M, Dal Sasso M. Thymol inhibits Candida albicans biofilm formation and mature biofilm. Int. J. Antimicrob. Agents, 31, 472-477 (2008).
17. Uppuluri P, Nett J, Heitman J, Andes D. Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob. Agents Chemother., 52, 1127-1132 (2008).
18. Cao YY, Cao YB, Xu Z, Ying K, Li Y, Xie Y, Zhu ZY, Chen WS, Jiang YY. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob. Agents Chemother., 49, 584-589 (2005).
19. Ramage G, Martínez JP, López-Ribot JL. Candida biofilms on implanted biomaterials: a clinically significant problem. FEM. Yeast Res., 6, 979-986 (2006).
20. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother., 41, 1482-1487 (1997).
21. Ramage G, Saville SP, Thomas DP, López-Ribot JL. Candida biofilms: an update. Eukaryot. Cell, 4, 633-638 (2005).
22. Weig M, Müller FM. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother., 45, 966-968 (2001).
23. Nishi I, Sunada A, Toyokawa M, Asari S, Iwatani Y. In vitro antifungal combination effects of micafungin with fluconazole, voriconazole, amphotericin B, and flucytosine against clinical isolates of Candida species. J. Infect. Chemother., 15, 1-5 (2009).
24. Guo Q, Sun S, Yu J, Li Y, Cao L. Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J. Med. Microbiol., 57, 457-462 (2008).
25. Oliveira ER, Fothergill AW, Kirkpatrick WR, Coco BJ, Patterson TF, Redding SW. In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata . Antimicrob. Agents Chemother., 49, 3544-3545 (2005).
26. Mitchell AP. Dimorphism and virulence in Candida albicans. Curr. Opin. Microbiol., 1, 687-692 (1998).
27. Kumamoto CA. Candida biofilms. Curr. Opin. Microbiol., 5, 608-611 (2002).
28. Jain P, Akula I, Edlind T. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother., 47, 3195-3201 (2003).
29. Chang WQ, Wu XZ, Cheng AX, Zhang L, Ji M, Lou HX. Retigeric acid B exerts antifungal effect through enhanced reactive oxygen species and decreased cAMP. Biochim. Biophys. Acta, 1810, 569-576 (2011).
30. Hall RA, Turner KJ, Chaloupka J, Cottier F, De Sordi L, Sanglard D, Levin LR, Buck J, Mühlschlegel FA. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot. Cell, 10, 1034-1042 (2011).
31. Shirtliff ME, Krom BP, Meijering RAM, Peters BM, Zhu J, Scheper MA, Harris ML, Jabra-Rizk MA. Farnesol-induced apoptosis in Candida albicans. Antimicrob. Agents Chemother., 53, 2392-2401 (2009).